Compare ESTA & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESTA | PHVS |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2018 | 2020 |
| Metric | ESTA | PHVS |
|---|---|---|
| Price | $81.45 | $30.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $86.86 | $41.82 |
| AVG Volume (30 Days) | ★ 418.0K | 333.2K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $61,208,000.00 | N/A |
| Revenue This Year | $28.05 | N/A |
| Revenue Next Year | $26.21 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 76.49 | N/A |
| 52 Week Low | $33.35 | $16.00 |
| 52 Week High | $85.56 | $33.33 |
| Indicator | ESTA | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 64.31 | 53.33 |
| Support Level | $63.71 | $24.55 |
| Resistance Level | $83.31 | $33.33 |
| Average True Range (ATR) | 4.78 | 1.42 |
| MACD | 1.12 | 0.11 |
| Stochastic Oscillator | 79.29 | 51.55 |
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.